EMD Serono Research & Development Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, EMD Serono Research & Development Institute sits in the top decile of US sponsors by registered trial count (#277 of 15,742 sponsors by registered trial count).
EMD Serono Research & Development Institute: 81 sponsored US clinical trials, 9 recruiting.
EMD Serono Research & Development Institute sponsors 81 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 40 completed. 17 of these trials are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 4 trials.
Top-decile sponsor footprint
EMD Serono Research & Development Institute ranks in the top decile of sponsors by registered trial count (#277 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
40 of 63 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
81 total, page 2 of 2
Study of Avelumab-M3814 Combinations
NCT03724890
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03631706
Tepotinib Hepatic Impairment Trial
NCT03546608
Phase I/II Study of Avelumab in Pediatric Cancer Participants
NCT03451825
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
NCT03306420
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
NCT03233230
M3541 in Combination With Radiotherapy in Solid Tumors
NCT03225105
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
NCT03284970
M8891 First in Human in Solid Tumors
NCT03138538
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
NCT03116971
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
NCT02994953
Efficacy and Safety of Atacicept in IgA Nephropathy
NCT02808429
A Phase II Study of M2951 in SLE
NCT02975336
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
NCT02784106
Abituzumab in SSc-ILD
NCT02745145
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
NCT02644278
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02625623
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
NCT02625610
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
NCT02537028
Avelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02576574
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
NCT02516813
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
NCT02395172
First in Human Study of M4344 in Participants With Advanced Solid Tumors
NCT02278250
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
NCT02155647
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
NCT01919164
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
NCT01772004
M6620 First in Human Study
NCT02157792
Oral Cladribine in Early Multiple Sclerosis (MS)
NCT00725985
CLARITY Extension Study
NCT00641537
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
NCT00436826
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 36 |
| Phase 2 | 22 |
| Phase 3 | 16 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the EMD Serono Research & Development Institute pipeline
9 recruiting of 81 indexed (11% open); 40 completed (49%).
Phase mix: 17 late (III/IV) vs 58 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
EMD Serono Research & Development Institute: open-pipeline peers nationwide
Peers matched on 81 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
EMD Serono Research & Development Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 81 trials (± recruiting share)
- The University of Tennessee, Knoxville · 81 trials · 7% recruiting
- TriHealth · 81 trials · 2% recruiting
- Christiana Care Health Services · 82 trials · 5% recruiting
- UCB Biopharma SRL · 82 trials · 20% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this EMD Serono Research & Development Institute page
81 registered trials is a research-attention snapshot, not an endorsement of EMD Serono Research & Development Institute or any single study.
- 9 of EMD Serono Research & Development Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition EMD Serono Research & Development Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
EMD Serono Research & Development Institute pipeline card: 81 registered trials from official public datasets.Report a data error.